ArticleScientific reports2025
Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management.Current rheumatology reports · 2026Review
- Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm.Medicina (Kaunas, Lithuania) · 2026Review
- High-plex spatial protein profiling of skeletal muscle biopsies in inflammatory myopathies using the MACSima™ imaging platform: A pilot study.Acta neuropathologica communications · 2026Article
- Expanded clinical and genetic characterization of autosomal recessive HMGCR-related muscular dystrophy.Journal of neuromuscular diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-HMGCR-positive immune-mediated necrotizing myopathy (IMNM), also anti-HMGCR myopathy, was initially considered as an exclusively skeletal muscular disease, observed in elderly patients with an acute onset. However, there is an increasing number of patients presenting greater clinical diversity than previously recognized. The aim of this study is to establish a comprehensive clinical-pathological classification for these patients, capturing the spectrum of disease presentations including both typical and atypical cases. We conducted a retrospective analysis and follow-up study of the clinical features, pathological manifestations, and treatment outcomes of 18 anti-HMGCR myopathy patients from Nanfang Hospital, along with data from 61 patients reported before. We defined 31 patients who presented with extra-muscular symptoms as overlap patients, while those who had merely muscular symptoms as non-overlap patients. Overlap patients had higher MMT-score, less muscular symptoms, specifically muscle weakness, and more extra-muscular symptoms, including ILD, arthralgia, weight loss and mostly skin involvement. Based on clinical, pathological, and genetic criteria, 12 peculiar patients were classified as MD-like patients. These cases, with earlier onset and longer duration, hardly had myalgia and extra-muscular symptoms, particularly skin involvement. Our study highlights the clinical and pathological heterogeneity of anti-HMGCR-positive IMNM. We identified a distinct subgroup of overlap patients, as well as MD-like patients. The classification system we proposed offers a practical framework for distinguishing these subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.